Table 2 Demographic characteristics and psychotropic drug prescriptions of community-dwelling older people with dementia in the three academic general practice research networks (2019–2021)
| Â | AHON Northern Region | FaMe-Net Eastern Region | RNFM Southern Region | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Â | 2019 | 2020 | 2021 | 2019 | 2020 | 2021 | 2019 | 2020 | 2021 |
Population, N | 1858 | 1916 | 1726 | 117 | 105 | 93 | 921 | 904 | 960 |
Age, mean ± SD | 83.0 ± 7.2 | 83.3 ± 7.1 | 83.2 ± 7.2 | 82.5 ± 7.7 | 82.9 ± 7.4 | 82.6 ± 7.7 | 83.0 ± 7.6 | 82.85 ± 7.6 | 83.0 ± 7.4 |
Gender, female, N (%) | 1138 (61.3) | 1181 (61.6) | 1041 (60.3) | 72 (61.5) | 61 (58.1) | 51 (54.8) | 575 (62.4) | 545 (60.3) | 589 (61.4) |
People who had at least one psychotropic drug prescription, N (%) | 820 (44.1) | 853 (44.5) | 795 (46.1) | 39 (33.3) | 45 (42.9) | 42 (45.2) | 383 (41.6) | 389 (43.0) | 391 (40.7) |
Antipsychotics, N (%) | 300 (16.2) | 314 (16.4) | 293 (17.0) | 9 (7.7) | 15 (14.3) | 13 (14.0) | 122 (13.3) | 139 (15.4) | 142 (14.8) |
Anxiolytics, N (%) | 202 (10.9) | 241 (12.6) | 211 (12.2) | 13 (11.1) | 14 (13.3) | 14 (15.1) | 98 (10.6) | 98 (10.8) | 103 (10.7) |
Hypnotics/Sedatives, N (%) | 236 (12.7) | 248 (12.9) | 225 (13.0) | 6 (5.1) | 9 (8.6) | 6 (6.5) | 110 (11.9) | 110 (12.2) | 101 (10.5) |
Antidepressants, N (%) | 345 (18.6) | 351 (18.3) | 331 (19.2) | 15 (12.8) | 18 (17.1) | 18 (19.4) | 154 (16.7) | 149 (16.5) | 158 (16.5) |
Anti-dementia drugs, N (%) | 207 (11.1) | 197 (10.3) | 172 (10.0) | 12 (10.3) | 9 (8.6) | 8 (8.6) | 86 (9.3) | 85 (9.4) | 75 (7.8) |
People who had at least one opioid prescription, N (%) | 305 (16.4) | 322 (16.8) | 321 (18.6) | 16 (13.7) | 11 (10.5) | 12 (12.9) | 128 (13.9) | 136 (15.0) | 160 (16.7) |
People who had at least one statin prescription, N (%) | 608Â (32.7) | 574 (30.0) | 513 (29.7) | 35 (29.9) | 31 (29.5) | 36 (38.7) | 287 (31.2) | 291 (32.2) | 330 (34.4) |